MAX SENNA MANO

(Fonte: Lattes)
Índice h a partir de 2011
16
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 30 Citação(ões) na Scopus
    Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
    (2016) BARROSO-SOUSA, Romualdo; SILVA, Danilo D. A. Fonseca Reis; ALESSI, Joao Victor Machado; MANO, Max Senna
    Luminal breast cancer, as defined by oestrogen and/or progesterone expression by immunohistochemistry, accounts for up to 75% of all breast cancers. In this population, endocrine therapy is likely to account for most of the gains obtained with the administration of adjuvant systemic treatment. The role of adjuvant chemotherapy in these patients remains debatable since it is known that only a small fraction of patients will derive meaningful benefit from this treatment whilst the majority will be exposed to significant and unnecessary chemotherapy-related toxicities, in particular the elderly and frail. Therefore, neoadjuvant endocrine therapy (NET) becomes an attractive option for selected patients with hormonal-receptor positive locally advanced breast cancer. In this review, we discuss the current role of NET and future perspectives in the field.
  • article 21 Citação(ões) na Scopus
    Biological therapies in breast cancer: Common toxicities and management strategies
    (2013) BARROSO-SOUSA, Romualdo; SANTANA, Iuri A.; TESTA, Laura; GAGLIATO, Debora de Melo; MANO, Max S.
    In recent years, a number of new molecules e commonly known as biological therapies e have been approved or are in late stages of regulatory evaluation for the treatment of advanced breast cancer. These innovative compounds have improved treatment efficacy and have probably contributed to the increase in survival length observed in some breast cancer subtypes. However, these agents are not deprived of toxicity, which can impair quality of life and may occasionally be life-threatening. In this article, we reviewed the most common toxicities associated with these drugs and provided a number of practical recommendations on their optimal clinical management.